RESEARCH ARTICLE

Short-term fish oil supplementation applied in presymptomatic stage of Alzheimer’s disease enhances microglial/macrophage barrier and prevents neuritic dystrophy in parietal cortex of 5xFAD mouse model

Milena Jović, Nataša Lončarević-Vasiljković, Sanja Ivković, Jelena Dinić, Desanka Milanović, Berislav Zlokovic, Selma Kanazir

1 Department of Neurobiology, Institute for Biological Research ‘Sinisa Stankovic’, University of Belgrade, Belgrade, Serbia, 2 Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States of America

* These authors contributed equally to this work.

natasa.loncarevic@ibiss.bg.ac.rs (NLV); selkan@ibiss.bg.ac.rs (SK)

Abstract

Dystrophic neurites and activated microglia are one of the main neuropathological characteristics of Alzheimer’s disease (AD). Although the use of supplements with omega-3 fatty acids has been associated with reduced risk and lessened AD pathology, it still remains elusive whether such a treatment could affect dystrophic neurites (DNs) formation and microglia/macrophage behavior in the early phase of disease. We analyzed the effects of short-term (3 weeks) fish oil supplementation on DNs formation, tau hyperphosphorylation, Amyloid-beta peptide 1–42 (Aβ42) levels and microglial/macrophage response to AD pathology in the parietal cortex of 4-month-old 5xFAD mice, a mouse model of AD. The present study shows for the first time that short-term FO supplementation applied in presymptomatic stage of AD, alters the behaviour of microglia/macrophages prompting them to establish a physical barrier around amyloid plaques. This barrier significantly suppresses DNs formation through the reduction of both Aβ content and tau hyperphosphorylation. Moreover, the short-term FO treatment neither suppresses inflammation nor enhances phagocytic properties of microglia/macrophages in the response to Aβ pathology, the effects most commonly attributed to the fish oil supplementation. Our findings suggest that fish oil consumption may play an important role in modulating microglial/macrophage response and ameliorating the AD pathology in presymptomatic stage of Alzheimer’s disease.

Introduction

Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease and the main form of progressive dementia in elderly [1]. It is characterized by cognitive deficits that initially
affect learning and memory, leading to the overall cognitive decline as the disease progresses. Although the AD clinical symptoms such as memory loss and impaired cognition occur in the older age it is estimated that the pathological processes underlying AD begin to develop even a few decades earlier [2]. Therefore, developing treatments for the presymptomatic phase of the disease is gaining in importance.

Defining feature of AD pathology is the formation of amyloid plaques, structures composed of fibrillar amyloid-β organized in a β-sheet conformation. Amyloid-β protein (Aβ) is the pivotal mediator of neuronal cell loss in the AD brain [3–5] with Aβ42 found to be the most toxic form [6, 7]. Plaques are mostly encircled by a halo of diffuse Aβ42, surrounded by dystrophic neurites (DNs) and activated glia [5, 8]. The areas of diffuse Aβ42 were recently named “hot-spots” and they are considered as the zones of greater neuro-toxicity [9]. Dystrophic neurites surrounding the plaques represent the initial phase of neurodegeneration. These varicose and beaded neurites are characterized by extensive microtubule disruption, due to the abnormal hyperphosphorylation of tau protein, and inhibited anterograde and retrograde trafficking [10, 11].

Prolonged microglial activation has an important role in the pathogenesis of AD [12, 13]. The distinctive feature of microglial behavior in the AD brain is their noticeable clustering around fibrillar Aβ deposits, which are also in close proximity to dystrophic neurites [14, 15]. However, the exact role of microglia in AD progression is still controversial.

The post-mortem studies as well as functional imaging studies have revealed that the changes in the parietal lobe, besides those in the temporal and frontal cortex, contribute to the AD progression [16–18]. Furthermore, these changes are gaining focus as a potential marker for the early diagnosis of AD in accordance with the 'last-developed–first-atrophied' concept [19]. The higher cognitive association areas, which mature after the primary areas, show the first signs of functional decline and grey matter atrophy [19, 20]. The involvement of the parietal cortex during the early phase of AD is likely due to its strong connectivity with other brain areas, a role in memory retrieval [21] and the wide range of cognitive functions relying on its proper functioning [22].

It has been shown that specific components of our diet can affect the progression of AD [23, 24] and docosahexaenoic acid (DHA) is one of them. The levels of DHA are decreased in brains and sera of AD patients [25, 26], and ω-3 polyunsaturated fatty acids (ω-3 PUFA) supplementation had become of a major interest as potential adjunctive treatment for AD patients. In humans, positive effects of DHA or eicosapentaenoic acid (EPA) supplementation have been seen only in cognitively healthy participants and participants with mild cognitive impairment [27]. Numerous clinical trials on patients with established AD revealed that EPA and DHA supplementation did not slow the rate of cognitive decline compared to the placebo [28]. In mouse AD models oral intake of PUFA’s and fish oil (FO), a rich source of essential PUFA’s—DHA and EPA has been associated with the decreased amyloid deposition in the early stages of AD and a reduced risk of AD if applied before the onset of AD pathology [29–32]. However, the effect of FO supplementation on neuritic pathology in the early phase of the disease has not been addressed so far.

Considering that the appearance of the DNs represents an early event that precedes neuronal loss, we aimed to examine whether the modification in dietary consumption via the addition of FO, in the presymptomatic phase of AD pathology, could attenuate or even prevent the progression of the DNs formation. To this purpose we have chosen the 5xFAD mouse model [33], which displays a rapid deposition of Aβ and a massive loss of pyramidal neurons [34] with the initial structural insults of neuronal cells appearing between 4 to 6 months of age [35]. We analyzed the effects of the short-term (3 weeks) FO treatment on DNs formation, p-Tau...
(Ser416) and Aβ42 levels, and on the distribution, number and localization of microglia/macrophages in 4-month-old 5xFAD mice.

Materials and methods

Animals and procedures

Ethics statement. All animal procedures were in compliance with Directive (2010/63/EU) on the protection of animals used for experimental and other scientific purposes and were approved by the Ethical Committee for the Use of Laboratory Animals (resolution No 01-06/13) of the Institute for Biological Research “Sinisa Stankovic”, University of Belgrade. Minimal numbers of animals were used and all efforts were made to minimize animal suffering.

Experimental animals and fish oil treatment. Three months old 5xFAD mice (B6SJL-Tg(APPsweFllon, PSEN1ΔE9) 6799Vas) from The Jackson Laboratory, stock number: 34840-JAX/5XFAD [33] were used for all experiments. Mice were divided into two experimental groups: control group (marked as 5xFAD) and treated group (marked as 5xFAD FO). The fish oil used in current study was ‘Omega 3’, commercial fish oil for human consumption standardized to 12% DHA and 18% EPA (Dietpharm-Atlantic Group, Croatia). Treated animals received 100 μl of commercial fish oil per day by oral gavage as previously described [30]. The control group received the same volume of the water, also by oral gavage. The animals were housed under standard conditions (23 ± 2˚C, 60–70% relative humidity, 12 h light/dark cycles, with the lights switched on at 07:00; free access to food and water; n = 3 per cage). The discomfort following oral gavage, capture, handling and restraint were minimized, due to the refinements in housing, husbandry and care and good practice for substance administration.

Sample preparation. Following 3 weeks of FO treatment, when reached age of 3 months and 3 weeks, animals were anesthetized with ketamine (Ketamidor, Richter pharm, Germany) in dosages of 250mg/kg. Mice were perfused with ice-cold phosphate-buffered saline (PBS), brains were harvested, and the cortex was extracted, quickly frozen, and stored at −80˚C until use for RNA and protein analysis.

RNA and protein analysis

Quantitative real-time PCR. Quantitative real-time PCR was performed using the ABI Prism 7700 Sequence Detection System (PE Applied Biosystems) to analyze the induction of inflammatory cytokine mRNAs, following the manufacturer’s instructions. Briefly, total RNA was extracted from the cortical tissue using TRIzol reagent. For cDNA synthesis, 1 μg of total RNA was transcribed with TaqMan reverse transcription reagents using random hexamers. The cDNA was stored at −20˚C until further use. Relative quantification of TNFα and IL-1β mRNAs was performed by real-time RT-PCR with the Applied Biosystems TaqManGene Expression Assays (TNFα - Cat No. 4331182, IL-1β –Cat.No. 4351372; Thermo Fisher Scientific). GAPDH was included as an endogenous control to correct for differences in interassay amplification efficiency (ID Rn99999916_s1; Applied Biosystems). Each sample was run in triplicate and the mean values of each Ct were used for further calculations. Quantification was performed by the $2^{-\Delta\Delta Ct}$ method. The results obtained by RT-PCR were analyzed in RQ Study add-on software for the 7700 v 1.1 SDS instrument, with a confidence level of 95% (P < 0.05).

Enzyme-linked immunosorbent assay. Enzyme-linked immunosorbent assay (ELISA) was used to quantify the cortical level of TNF-α. TNF-α ELISA kit (ab100747, Abcam) was used according to the manufacturer’s recommendations. Tissue was homogenized on ice in the extraction buffer recommended by the manufacturer (100 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate) with 1 mg/
mL of protease inhibitor cocktail (cOmplete, Sigma-Aldrich) and 0.01 mg/mL of phosphatase inhibitor cocktail (P5726, Sigma-Aldrich). The protein concentrations were determined using a Micro BCA protein assay kit (Pierce, Rockford, IL). The absorbance at 450 nm was measured with an iMark Microplate Absorbance Reader (Bio-Rad).

**Western blot analysis.** The extracted cortical tissue was homogenized in 10 vol (w/v) of RIPA buffer (50 mM Tris-Cl pH 7.5, 150 mM NaCl, 1% NP-40, 0.1% SDS, 10 mM EDTA pH 8.0, 10 mM EGTA pH 7.2, 0.5% Triton X-100), followed by centrifugation (21 000 rcf, 30 min, 4°C); the supernatant was collected. Protein concentrations were determined using the Micro BCA Protein Assay Kit (Pierce Biotechnology). Equal amounts of proteins (30 μg per lane) were loaded and separated by 10% SDS acrylamide gel electrophoresis and blotted onto nitrocellulose membranes (Amersham Bioscience). The membranes were blocked at room temperature for 1 h in 5% nonfat dry milk in Tris-buffered saline/0.1% Tween 20 (TBST). The membranes were incubated with rabbit monoclonal anti-phospho-Tau (Ser416) (1:500; D7U25, Cell Signaling Technologies, USA) in TBST, overnight at +4°C. The membranes were then incubated with the HRP labeled secondary anti-rabbit antibody (1:2000; sc-2370, Santa Cruz, USA) in TBST for 1 h at room temperature. Three subsequent washes with 0.1% TBST were performed between each step. The signal was detected by enhanced chemiluminescence (ECL, Amersham Bioscience) and exposure of an X-ray film. All films were analyzed by densitometry using the computerized image analysis program ImageQuant ver. 5.2 (Amersham). The Ponceau S staining of the membranes served as endogenous control. The relative values of the signals (normalized to the corresponding Ponceau S staining) were determined and further statistically analyzed.

**Histological analysis**

**Preparation of tissues for histological analysis.** Following the perfusion with ice-cold phosphate-buffered saline (PBS), brains were harvested, and one hemi-brain drop fixed in 4% paraformaldehyde/PBS and cryopreserved in graded sucrose solutions (10–30% w/v sucrose/PBS) for sectioning. The brains were frozen in isopentane, cooled on dry ice and stored at -80°C. Every third coronal section (20 μm thick) was collected and stored at -20°C.

**Amyloid plaque staining.** For amyloid plaque staining, Thioflavin S (ThioS) and AmyloGlo (BioSense, TR-300-AG) staining was used. ThioS was used for double staining with amyloid beta 42 antibody. Following protocol for amyloid beta 42 immunostaining, sections were washed three times in 0.01 PBS, and incubated in 0.01% ThioS solution in 50% ethanol for 8 min at RT. Stained sections were washed briefly in 80% and 96% ethanol, rinsed in distilled water and mounted onto glass slides using fluorescent mounting medium (Dako). AmyloGlo staining was used for triple labeling with ionized calcium binding adaptor molecule 1 (Iba-1) and amyloid 4g8 antibodies. Before incubation with antibodies sections were transferred into a 70% solution of ethanol for 5 minutes at RT. The slides were then rinsed in distilled water for 2 minutes. Sections were transferred for 10 min to a 1:100 of AmyloGlo dissolved in 0.9% saline solution, rinsed in 0.9% saline solution for 5 minutes, and briefly rinsed in distilled water. Following AmyloGlo staining, sections were incubated with Iba-1 and amyloid 4g8 antibodies.

**Immunohistochemical analysis**

**Immunofluorescence.** Sections were blocked in 1% bovine serum albumin (BSA) in PBS for 1h in RT, incubated overnight at 4°C with primary antibodies listed in Table 1, followed by appropriate secondary antibodies (anti-mouse or anti-rabbit conjugated to Alexa 488 or 568; Invitrogen) used at the 1:250 concentration in PBS for 2h at room temperature (RT). Sections incubated in parallel without primary antibody were included as negative controls for
autofluorescence and background binding of the secondary antibody. Sections were mounted with Fluorescent Mounting Medium (Dako).

**Quantitative analysis of Aβ42 clusters and SMI31-labeled DNs.** Images were captured on an Axio Observer Microscope Z1 using an AxioVision 4.6 software system (Carl Zeiss, Germany) at a magnification of 5×, 10× and 40×. For quantification of Aβ42 clusters and SMI31-labeled dystrophic neurites we used available software provided by the National Institute of Health (NIH, USA)—Image J, Version 1.74. The software analyzed each cross-section. We have designated a threshold of the fluorescence intensity. When setting the limit value for analysis we have opted for the automatic value (Maximum Entropy), instead of manual adjustment, in order to perform further analysis equally in all cross-sections and to reduce faults. Based on given parameters we produced values of the surface of Aβ42 clusters. The values were further processed statistically and expressed as percentage of parietal cortex covered by Aβ42 and average surface of Aβ42 clusters.

Analyses of SMI31-positive spheroids number and % of area covered with SMI31 immunostaining were done using Image J with threshold processing (Max Entropy) and low surface area limit set to 50 μm². The low surface area limit was set in order to exclude SMI31-positive particles of lower surface which correspond to SMI31 immunostaining of normal (non-dystrophic) neurites. Based on given parameters we produced values of the surface of SMI31-positive spheroids number and % of area. The values were further processed statistically.

**Confocal microscopy and image analysis of colocalization between Iba-1 and Aβ 4G8.** Amyloid β and Iba-1 labelling were visualized with a Leica TSC SP8 confocal microscope (Leica Microsystems) equipped with 405/488/552 nm lasers using 40×/1.30 oil immersion lens. Images were taken with a step size of 1μm. Emission of fluorescently labelled Aβ and Iba-1 were collected sequentially. All images were taken with a 1024×1024 pixel resolution and 8-bit colour depth. Colocalization analysis was performed in ImageJ software (NIH, USA) using JACoP plugin [36] and the degree of colocalization between Iba-1 and Aβ4G8 was measured using the Pearson correlation coefficient (PCC). PCC measures the strength of a linear relationship between fluorescent intensities from the two images and produces values ranging from 1 (perfect positive correlation) to -1 (perfect inverse correlation), with 0 representing a random distribution [37].

**Confocal microscopy and quantification of Iba1-positive microglia/macrophages.** For Iba-1 imaging conditions were the same as described above. The number of Iba1-positive microglia/macrophages were counted in layers III to VI in parietal part of the somatosensory cortex in 1 field per section under the area of the screen (400μm x 550μm) in 3 sections per animal (n = 8 animals per each group). The sections were analyzed by a researcher unaware of the treatment.

**Confocal microscopy and quantification of plaque perimeter covered by microglia/macrophages.** For Iba-1 and Amylo Glo imaging conditions were the same as described above. Confocal images of plaques selected for their similar size, location and cortical layer (layers III to VI in parietal part of the somatosensory cortex) were obtained for quantitative imaging using a a Leica TSC SP8 confocal microscope. Images were numbered randomly and blinded.

### Table 1. Primary antibodies used in this study.

| antibody against  | catalogue No. | host/clonality      | manufacturer  | Dilution |
|-------------------|---------------|---------------------|---------------|----------|
| Amyloid β 42      | 700254        | rabbit monoclonal   | Invitrogen    | 1:500    |
| Purified Abeta 4G8| 800701        | mouse monoclonal    | BioLegend     | 1:2000   |
| SMI31             | LN#E10214GF   | mouse monoclonal    | Covance       | 1:5000   |
| Iba-1             | 019–19741     | rabbit polyclonal   | WAKO          | 1:250    |
for analysis. All images were analyzed in ImageJ software. Five optical slices through the center of the plaque were used for analysis. On each slice, the intersection between the tips of microglia/macrophages process and the plaque perimeter were identified manually. The proportion of the plaque perimeter covered by microglia/macrophage processes was calculated by summing the arcs of plaque perimeter that colocalized with microglial/macrophage processes. For each measurement, the average of results for 5 optical slices was reported as a measurement for the individual plaque.

**Statistical analysis.** Significant differences between the data sets were determined using STATISTICA software, Ver. 6.0, StatSoft. Further statistical analysis was made using relative values. Considering that data did not meet the criteria of a normal distribution, nonparametric Mann-Whitney U test was used for comparisons among two experimental groups. Statistical significance was set at \( P < 0.05 \).

**Results**

**Three weeks of fish oil supplementation ameliorates neuritic dystrophy and tau hyperphosphorylation in parietal cortex of 5xFAD mice**

Swollen, dystrophic neurites surrounding amyloid plaques represent one of the hallmarks of AD pathology. Since neuritic dystrophy inevitably leads to neuronal cell death, it is of vital interest to prevent this aspect of AD pathology. In order to determine whether fish oil supplementation can affect the neuritic dystrophy we stained sections from the parietal cortex of the control and FO-treated 5xFAD mice with SMI31 antibody. In non-supplemented 5xFAD mice in the vicinity of amyloid plaques, SMI31 staining revealed swollen, dystrophic neurites (Fig 1A and 1D asterisks). However, the analysis of brain sections of FO-supplemented 5xFAD animals showed that most of the neurites have normal (non-dystrophic) appearance (Fig 1B and 1E), and are similar to neurites observed in the cortex of age-matched wild-type controls (Fig 1C and 1F).

In order to size the effect of the FO treatment, we measured the SMI31-positive spheroids number and % of SMI31 immunopositive area in the parietal cortex of untreated and FO-treated 5xFAD animals (Fig 1J). The analysis revealed that FO treatment significantly lowered the number of SMI31-positive spheroids (by 48.6%, MWU test, \( p = 0.03 \)) and the percentage of the area covered by SMI31 (by 50.62%, MWU test, \( p = 0.018 \)) when compared to untreated 5xFAD animals (Fig 1K). Thus, the short-term (3 weeks) fish oil supplementation is able to suppress neuritic dystrophy in the parietal cortex of 5xFAD mice.

Dystrophic neurites are characterized by abnormally hyperphosphorylated tau protein that becomes incompetent in maintaining the stability of microtubules. Western blot analysis of p-Tau (Ser416) was performed in order to determine whether fish oil supplementation suppresses neuritic dystrophy by affecting the level of tau hyperphosphorylation. The analysis revealed that the level of p-Tau (Ser416) was significantly decreased (by 36%) in FO-treated as compared to untreated 5xFAD animals (MWU, \( p = 0.033 \)) (Fig 1L and 1M).

**Fish oil supplementation reduces the area covered by Aβ42 and the average size of Aβ42 clusters in the parietal cortex**

It is widely accepted that amyloid β (Aβ42) that surrounds amyloid plaques represents the main cause of neuritic dystrophy in Alzheimer’s pathology. Since we showed that fish oil supplementation is able to suppress neuritic dystrophy in the parietal cortex of 5xFAD mice (Fig 1), we wanted to assess whether it is able to alter the total amount of Aβ42 in this cortical region. The immunostaining of parietal cortex of control and FO-treated 5xFAD mice with
anti-Aβ42 antibody (Fig 2) revealed that in both control and FO-treated 5xFAD mice, Aβ42 localization was observed mainly surrounding the plaques of insoluble amyloid β (stained with

Fig 1. FO supplementation ameliorates neuritic dystrophy through suppression of abnormal tau hyperphosphorilation in the parietal cortex of 5xFAD mice. (A and D) Axonal dystrophies (arrows) surrounding amyloid plaques (P) in 4-month-old 5xFAD mice; (B and E) Brains of FO-supplemented 5xFAD mice showing significant suppression of dystrophic neurites (G-I) Print screen of ImageJ SMI31 analysis (Max Entropy threshold). (J) Percentage of SMI31-positive spheroids larger than 50μm² in untreated and FO-treated 5xFAD mice. (K) Percentage of SMI31 coverage of parietal cortex in untreated and FO-treated 5xFAD mice (low surface area limit set to 50μm²). (L) Representative immunoblot of p-Tau (Ser416) in untreated and FO-treated 5xFAD mice. (M) Changes in p-Tau (Ser416) protein in the cortex of 5xFAD and 5xFAD FO mice were revealed by Western blot analysis. The data represent mean ± S.E.M. value;  *p < 0.05. Scale bar (D-F) - 5μm.

https://doi.org/10.1371/journal.pone.0216726.g001

anti-Aβ42 antibody (Fig 2) revealed that in both control and FO-treated 5xFAD mice, Aβ42 localization was observed mainly surrounding the plaques of insoluble amyloid β (stained with
Thioflavin-S) (Fig 2C–2H). In order to size the effect of the FO treatment, we measured the surface area of the parietal cortex stained with anti-Aβ42 (Fig 2A and 2B). The analysis of surface percentage immunostained with Aβ42 revealed that FO treatment significantly lowered (by 49.14%) the area covered by Aβ42 when compared to the untreated 5xFAD animals (MWU test, p = 0.0047) (Fig 2I). Moreover, Image J analysis revealed that FO supplementation significantly reduced the average size of Aβ42 clusters (by 29.6%) in the parietal cortex of treated 5xFAD animals when compared to the untreated 5xFAD animals (MWU test, p = 0.0209) (Fig 2J).

The Aβ42 “hot-spots” are the sites of greater neurotoxicity and we wanted to see if the decrease in Aβ42 covered surface around plaques relates to the lower occurrence of DNs. Double staining with Aβ42 and SMI31 antibodies revealed that the areas with higher incidence of DNs display the greater Aβ42 halo around the plaques (AmyloGlo+) (Fig 3A–3D). The opposite was observed in FO treated 5xFAD animals: the decreased surface of the Aβ42 halo overlaps with the decreased incidence of swollen, dystrophic neurites (Fig 3E–3H).

**Fish oil supplementation does not affect the levels of proinflammatory cytokines and phagocytosis of Aβ42 by microglia/macrophages in the parietal cortex of 5xFAD mice**

Since the phagocytosis of Aβ protein by microglia/macrophages has been proposed as an Aβ-lowering mechanism in AD [38, 39], we wanted to see whether the observed increase in Iba-1 + cell number correlates with the increased colocalization of Aβ42 in microglia surrounding...
Fish oil supplementation significantly elevates the total number of microglia/macrophages in the parietal cortex and the average number of these cells associated with amyloid plaques, accompanied by the increased plaque envelopment.

Since ω-3 PUFAs may be protective against AD by modulating the immune response to Aβ [42], we wanted to see whether the FO treatment had an effect on the number and distribution of Iba-1 positive microglia/macrophages in 5xFAD mice. The quantification of microglia/
macrophages number revealed that the FO treatment significantly increased (40.5%) the number of Iba-1+ cells in the parietal cortex of 5xFAD mice compared to the untreated mice (Fig 5A–5C) (MWU test, p = 0.00172). Namely, an average of 84 microglia/macrophages per field was detected in fish oil-supplemented animals, while the significantly lower number of 50 microglia/macrophages per field was detected in non-supplemented animals.

Considering that fish oil supplementation led to the increase in an overall number of microglia/macrophages in the parietal cortex, we next examined whether it affected the number of plaque-associated microglia/macrophages. To that end we counted a number of Iba-1+ cells with their processes pointed towards and permeated with the plaque surface of single plaques (Fig 5D and 5E). An average of 2.93 plaque-associated Iba-1+ cells per single plaque was counted in non-treated 5xFAD animals, while significantly higher number of 4.01 plaque-
Fig 5. FO supplementation affects the total number of microglia/macrophages, average number of plaque associated microglia/macrophages and plaque envelopment. (A) Representative confocal images of Iba-1 immunolabeled microglia/macrophage in parietal cortex in untreated and (B) FO treated 5xFAD mouse. (C) Quantification of number of Iba-1 positive microglia/macrophages in parietal cortex of untreated vs. treated 5xFAD mice in from 8 animals for each group. Data represents mean ± s.e.m. (D) Representative confocal images of Iba-1 immunolabeled microglia/macrophages around AmyloGlo-labeled amyloid plaques in untreated and (E) FO treated 5xFAD mice, larger magnification. (F) Quantification of number of plaque-associated microglia/macrophage in untreated vs. treated 5xFAD mice in n > 90 plaques from 8 animals for each group. Data represents mean ± s.e.m. (G) Representative confocal images of Iba-1 immunolabeled microglial/macrophage processes (green) contacting AmyloGlo-labeled amyloid plaques in untreated and (H) FO-treated 5xFAD mice. (I) Microglia/macrophage coverage was quantified as the percentage of plaque perimeter contacted by microglial/macrophage processes in n > 90 plaques from 8 animals for each group. Data represents mean ± s.e.m. (J,K) Representative confocal images of Iba-1 immunolabeled microglia/macrophages (green) and Aβ42 (red) mutual exclusion. Scale bar (A, B) - 50 μm. Scale bar (D, E, G, H) - 10 μm. Scale bar (J, K, L, M) - 5 μm.

https://doi.org/10.1371/journal.pone.0216726.g005
associated Iba-1+ cells (MWU test, \( p = 0.000140 \)) was counted in the parietal cortex of fish oil-supplemented 5xFAD animals (Fig 5F). We next sought to understand whether the elevated number of microglia/macrophages aggregating around plaques also affected the degree of plaque surface coverage by processes of these immune cells (Fig 5G and 5H). Our results revealed that plaque surface coverage by microglial/macrophage processes was significantly elevated in the FO-supplemented 5xFAD animals (MWU test, \( p < 0.00001 \)) and amounted to 62.55% of total plaque surface, as compared to 49.32% of coverage in non-supplemented animals (Fig 5I).

Moreover, given that microglial/macrophage processes represent neuroprotective barrier [9] the increased number of plaque-associated microglia/macrophages observed in FO-supplemented mice might be the consequence of neuroprotective properties of fish oil. Namely, our data showed that plaque regions covered by microglia/macrophage had fewer dystrophic neurites than those without microglial/macrophage processes (Fig 5J and 5K). Since microglial/macrophage process distribution around the plaques is mutually exclusive with the localization of A\( \beta \)42 (Fig 5L and 5M), the increased microglial/macrophage envelopment of amyloid plaques in FO-supplemented mice might be responsible for the observed reduction of A\( \beta \)42 in the parietal cortex of this animals. Thus, these data strongly suggest that increased envelopment of amyloid plaques by microglial/macrophage processes represent a critical determinant of the neuroprotection driven by FO supplementation.

**Discussion**

Neurodegeneration in AD is a process that evolves during prolonged period of time and when the first clinical symptoms occur the disease is so far advanced that it leaves little or no options of reverting damage that has been already inflicted. The onset of neuritic dystrophy appears in the early phase of pathology, the latent phase, thus presenting the window of opportunity for the potential treatments that can suppress the development of these pathological changes and disrupt the progression of the disease. The 5xFAD mouse represents a valuable model for studying the effects of different treatments on various aspects of AD related pathology as this AD mouse model develops the profound loss of cortical neurons by 12 months, with the initial structural insults appearing between 4 to 6 months of age [34, 35].

In the present study 5xFAD mice were treated for three weeks with FO in the latent phase of disease when the changes in animal behavior are not yet apparent. We demonstrated that even a short treatment with FO reduced the A\( \beta \)42 accumulation and DNs formation around the plaques, concurrently increasing the average microglial number and microglial plaque envelopment in the parietal cortex of 5xFAD mice.

So far, the progression of neuritic dystrophy has been linked to the A\( \beta \) protein accumulation around amyloid plaques in the AD brain [3, 43, 44]. It has been shown that A\( \beta \) mediates microtubule disruption via abnormal hyperphosphorylation of tau [45], and microtubule-based transport impairment that leads to the development of neuritic dystrophy and increased APP cleavage and A\( \beta \) production within these dystrophic neurites [5]. The microtubule-associated protein tau plays a major role in maintaining the normal morphology of the neurons, as it promotes microtubule assembly and stabilization. In the brain of AD patients, tau protein is abnormally hyperphosphorylated and thus become incompetent in maintaining the stability of the microtubules, directly affecting the morphology and biological functions of the neurons. The recent data from the study in 5xFAD mice [46] supports the prevailing amyloid cascade hypothesis [47], implying that hyperphosphorylation of tau is downstream of amyloid pathology, triggering the neurodegeneration and severe neuronal loss. Indeed, the anti-A\( \beta \) antibody treatment induces the reduction in the number and size of dystrophic neurites as soon as 3 days after A\( \beta \) deposits were cleared by this treatment [48]. The present study revealed that the
short-term FO supplementation significantly suppressed DNs formation through the reduction of both Aβ content and tau hyperphosphorylation. This is in accordance with previous research showing that DHA increases neuronal survival by directing amyloidogenic processing of APP towards nonamyloidogenic processing, effectively reducing Aβ release [31]. In addition, DHA treatment has also been shown to improve microtubule stability and maintenance of active compensatory microtubule-associated proteins [49].

Besides the reduction of Aβ content, the anti-inflammatory action of fish oil is also well described [40, 41, 50–52], and many of its pleiotropic effects have been ascribed to this property. Numerous data indicate that DHA anti-inflammatory effects are accompanied by an increase in the phagocytic activity of microglial cells [53, 54]. Recent studies of fish-derived omega-3 supplementation in patients with mild cognitive impairment have shown polarization of macrophages to an intermediate M1-M2 phenotype that is optimal for Aβ phagocytosis and the stabilization of cognitive decline [54, 55]. However, our study showed for the first time that short-term FO supplementation neither suppresses inflammation nor enhances phagocytic properties of immune cells in the response to Aβ pathology, but it changes the behaviour of these cells prompting them to establish a physical barrier around amyloid plaques.

The classical M1 activation of macrophages is characterized by elevated pro-inflammatory cytokines and impaired phagocytic capacity [56, 57], while the M2 state is characterized by secretion of anti-inflammatory cytokines and elevated phagocytic capacity [58–60]. However, the M1/M2 activation states represent the polar extremes of myeloid cell activation. There is a large diversity and graduation of phenotypic states in peripheral monocyte-derived macrophages, in particular under conditions of chronic inflammation [61, 62]. It is increasingly recognized that responses of microglia to CNS injuries are more complex than M1 and M2 macrophage activation, and are likely modulated by the type of injury, timing and environment; possibly involving a continuum of states [63, 64].

It has been shown that activated microglia migrate to amyloid deposits early in the pathogenesis of a mouse model of AD [65]. However, in vivo studies monitoring plaque-microglia interaction did not observe any plaques being cleared by this microglial response [65]. This suggests that, unless further activated [66], microglia do not successfully clear plaques but instead may well restrict their growth, leading to the observed steady state of plaque size after initial formation [9, 65].

It is, therefore, possible that short-term fish oil treatment brings microglia/macrophages in a state of increased migration towards Aβ deposits enhancing the envelopment of amyloid plaques by their processes, without affecting inflammatory or phagocytic properties of these cells.

The importance of these findings is strengthened with the recent discovery that plaque micro-regions not covered by microglia represent hot-spots rich in the proteofibrillar Aβ42 [5], a form of Aβ that is significantly more neurotoxic than larger Aβ aggregates[67, 68]. The accumulated microglial cells act as a barrier that reduces the uncovered plaque surface and consequently the number of hotspots of active Aβ polymerization. The microglial barrier can restrict further polymerization of the growing amyloid fibrils preventing their elongation and promoting their bending, thus shielding the surrounding neurites [5]. The strong enhancement of microglial/macrophage plaque envelopment observed in FO treated 5xFAD mice can thus represent the mechanism underlying the observed reduction of Aβ42 hotspots around plaques in the parietal cortex. The substantial neuritic dystrophy around fibrillar plaques with greater proteofibrillar Aβ42 halo further highlights the necessity for the reduction of, not the number of plaques, but the amount of proteofibrillar Aβ42 as the major cytotoxic component. As a rule, the overall degree of neuritic dystrophy around plaques is inversely correlated to the extent of microglia/macrophage plaque envelopment. However, the diffident reduction of DNs after anti-Aβ immunotherapy [48], regardless of a robust increase in the microglia...
envelopment, implies that negative effects of the immunotherapy might counteract the beneficial effects of the microglia barrier. The failure of such [69] and numerous other promising therapeutic approaches can be partly explained with their implementation in the later phase of the AD progression.

Condello and colleagues [9] emphasized that microglia envelopment was most effective around smaller plaques suggesting that microglia barrier is most prominent at the initial stages of fibrillar amyloid deposition and becomes less effective as the disease progresses. Similarly, studies of microglia ablation in later stages of amyloidosis did not show any effect on plaque number or neuritic dystrophy [70] indicating that it is increasingly difficult to treat symptoms after the disease occurrence. Therefore, the enhancement of the microglial/macrophage envelopment of the plaques and the consequential reduction of Aβ42 hotspots induced by the FO supplementation suggests a novel mechanism by which fish oil can inhibit the development of neuritic dystrophy.

This study provides evidence that neuroprotective effect of FO in the early phase of AD progression occurs through the modulation of microglia/macrophage number and behavior and underlines the necessity to elucidate the responsible molecular pathways. Several mechanisms are known to underlie omega-3-mediated neuroprotection, such as suppression of cell death, inhibition of inflammation, and promotion of neurogenesis [31]. In addition, omega-3 PUFA modulates microglia cell number and morphology in response to intracerebroventricular amyloid-β 1–40 in mice [42]. Also, documented DHA effects on lipid rafts, cholesterol homeostasis, amyloid burden and microtubule stability [12], can be responsible for the therapeutic effects of the FO supplementation. Aβ pathology is initiated at least two decades before cortical tau pathology and the onset of clinical AD symptoms[71,72], giving ample time for the preventive treatments to either delay or to ameliorate this debilitating disease. This is why the development of medications for early prevention and treatment, in accordance with the global epidemiological status, are considered a vital research goal.

Conclusions

The present study shows for the first time that short-term FO supplementation in presymptomatic stage of AD, changes the behaviour of microglia/macrophages prompting them to establish a physical barrier around amyloid plaques. This barrier significantly suppresses DNAs formation through the reduction of both Aβ content and tau hyperphosphorylation. It is interesting however, that short-term FO treatment neither suppresses inflammation nor enhances phagocytic properties of microglia/macrophages in the response to Aβ pathology, the effects most commonly attributed to the fish oil supplementation.

Revealing whether fish oil affects both microglia and macrophages in the same way, and understanding the precise mechanisms involved in this newly identified effect of fish oil, represent the future directions in elucidating its neuroprotective capacity in AD and other neurodegenerative disorders. Fish oil as a potential treatment in AD patients has a narrow window of applicability limited to the early stages of the disease. However, FO supplementation as a prophylactic intervention targeted to the enhancement of microglia/macrophage barrier may represent a promising strategy that offers effective neuroprotection.

Author Contributions

Conceptualization: Milena Jović, Nataša Lončarević-Vasiljković, Sanja Ivković, Selma Kanazir.

Data curation: Nataša Lončarević-Vasiljković, Selma Kanazir.
Formal analysis: Milena Jović, Jelena Dinić, Desanka Milanović.
Investigation: Milena Jović, Nataša Lončarević-Vasiljković.
Software: Milena Jović, Nataša Lončarević-Vasiljković, Jelena Dinić, Desanka Milanović.
Supervision: Selma Kanazir.
Validation: Milena Jović.
Visualization: Milena Jović, Jelena Dinić, Desanka Milanović.
Writing – original draft: Milena Jović, Nataša Lončarević-Vasiljković.
Writing – review & editing: Nataša Lončarević-Vasiljković, Sanja Ivković, Berislav Zlokovic, Selma Kanazir.

References
1. Schaeffer EL, Figueiro M, Gattaz WF. Insights into Alzheimer disease pathogenesis from studies in transgenic animal models. Clinics (Sao Paulo). 2011; 66 Suppl 1:45–54.
2. Laurent S, Ejtehadi MR, Rezaei M, Kehoe PG, Mahmoudi M. Interdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer’s disease. RSC Advances. 2012; 2(12):5008–33.
3. Mokhtar SH, Bakhuraysah MM, Cram DS, Petratsos S. The Beta-amyloid protein of Alzheimer’s disease: communication breakdown by modifying the neuronal cytoskeleton. Int J Alzheimers Dis. 2013; 2013:910502. https://doi.org/10.1155/2013/910502 PMID: 24416616
4. Tanzi RE. The genetics of Alzheimer disease. Cold Spring Harb Perspect Med. 2012; 2(10).
5. Sadleir KR, Kandalepas PC, Buggia-Prevot V, Nicholson DA, thinakaran G, Vassar R. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Abeta generation in Alzheimer’s disease. Acta Neuropathol. 2016; 132(2):235–56. https://doi.org/10.1007/s00401-016-1558-9 PMID: 26993139
6. Younkin SG. The role of A beta 42 in Alzheimer’s disease. J Physiol Paris. 1998; 92(3–4):289–92. PMID: 9789825
7. Barucker C, Bittner HJ, Chang PK, Cameron S, Hancock MA, Liebsch F, et al. Abeta42-oligomer Interacting Peptide (AIP) neutralizes toxic amyloid-beta42 species and protects synaptic structure and function. Sci Rep. 2015; 5:15410. https://doi.org/10.1038/srep15410 PMID: 26510576
8. Prokop S, Miller KR, Heppener FL. Microglia actions in Alzheimer’s disease. Acta Neuropathol. 2013; 126(4):461–77. PMID: 24224195
9. Condello C, Yuan P, Schain A, Gutzendl er J. Microglia constitute a barrier that prevents neurotoxic pr tofibrillar Abeta42 hotspots around plaques. Nat Commun. 2015; 6:6176. https://doi.org/10.1038/ncomms7176 PMID: 25630253
10. Vickers JC, Dickson TC, Adlard PA, Saunders HL, King CE, McCormack G. The cause of neuronal degeneration in Alzheimer’s disease. Prog Neurobiol. 2000; 60(2):139–65. PMID: 10639052
11. Woodhouse A, West AK, Chuckowree JA, Vickers JC, Dickson TC. Does beta-amyloid plaque formation cause structural injury to neuronal processes? Neurotox Res. 2005; 7(1–2):5–15. PMID: 15639794
12. Miller KR, Streit WJ. The effects of aging, injury and disease on microglial function: a case for cellular senescence. Neuron Glia Biol. 2007; 3(3):245–53. https://doi.org/10.1017/S1740925X07000036 PMID: 18634615
13. Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC. Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease. Neurobiol Aging. 2004; 25(5):665–74. https://doi.org/10.1016/j.neurobiolaging.2004.01.007 PMID: 15172746
14. Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer’s disease mice. J Neurosci. 2008; 28(33):8354–60. https://doi.org/10.1523/JNEUROSCI.0616-08.2008 PMID: 18701698
15. Liu Z, Condello C, Schain A, Harb R, Gutzendler J. CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-beta phagocytosis. J Neurosci. 2010; 30(50):17091–101. https://doi.org/10.1523/JNEUROSCI.4403-10.2010 PMID: 21159979
16. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239–59. PMID: 1759558
17. Braak H, Braak E. Evolution of the neuropathology of Alzheimer’s disease. Acta Neurol Scand Suppl. 1996; 165:3–12. PMID: 8740983
18. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005; 25(34):7709–17. https://doi.org/10.1523/JNEUROSCI.2177-05.2005 PMID: 16120771
19. Jacobs HI, Van Boxtel MP, Uylings HB, Gronenschild EH, Verhey FR, Jolles J. Atrophy of the parietal lobe in preclinical dementia. Brain Cogn. 2011; 75(2):154–63. https://doi.org/10.1016/j.bandc.2010.11.003 PMID: 21130554
20. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011; 1(1):a006189. https://doi.org/10.1101/cshperspect.a006189 PMID: 22229116
21. Cabeza R. Role of parietal regions in episodic memory retrieval: the dual attentional processes hypothesis. Neuropsychologia. 2008; 46(7):1813–27. https://doi.org/10.1016/j.neuropsychologia.2008.03.019 PMID: 18439631
22. Jacobs HI, Van Boxtel MP, Jolles J, Verhey FR, Uylings HB. Parietal cortex matters in Alzheimer’s disease: an overview of structural, functional and metabolic findings. Neurosci Biobehav Rev. 2012; 36(1):297–309. https://doi.org/10.1016/j.neubiorev.2011.06.009 PMID: 21741401
23. Kamphuis PJ, Scheltens P. Can nutrients prevent or delay onset of Alzheimer’s disease? J Alzheimers Dis. 2010; 20(3):765–75. https://doi.org/10.3233/JAD-2010-091558 PMID: 20820261
24. Scheltens P, Kamphuis PJ, Verhey FR, Olde Rikkert MG, Wurtman RJ, Wilkinson D, et al. Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial. Alzheimers Dement. 2010; 6(1):1–10 e1. https://doi.org/10.1016/j.jalz.2009.10.003 PMID: 20129316
25. Astarita G, Jung KM, Berchtold NC, Nguyen VQ, Gillen DL, Head E, et al. Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer’s disease. PLoS One. 2010; 5(9):e12538. https://doi.org/10.1371/journal.pone.0012538 PMID: 20838618
26. Fraser T, Tayler H, Love S. Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer’s disease. Neurochem Res. 2010; 35(3):503–13. https://doi.org/10.1007/s11064-009-0087-5 PMID: 19904605
27. Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci. 2015; 7:52. https://doi.org/10.3389/fnagi.2015.00052 PMID: 25954194
28. Cederholm T, Salem N Jr., Palmblad J. omega-3 fatty acids in the prevention of cognitive decline in humans. Adv Nutr. 2013; 4(6):672–6. https://doi.org/10.3945/an.113.004556 PMID: 24228198
29. Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci. 2005; 25(12):3032–40. https://doi.org/10.1523/JNEUROSCI.4225-04.2005 PMID: 15788759
30. Green KN, Martinez-Coria H, Khashwji H, Hall EB, Yurko-Mauro KA, Ellis L, et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci. 2007; 27(16):4385–95. https://doi.org/10.1523/JNEUROSCI.0057-07.2007 PMID: 17442823
31. Grimm MO, Kuchenbecker J, Groszen S, Burg VK, Hundsdorfer B, Rothhaar TL, et al. Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms. J Biol Chem. 2011; 286(16):14028–39. https://doi.org/10.1074/jbc.M110.182329 PMID: 21324907
32. Milanovic D, Petrovic S, Brkic M, Avramovic V, Perovic M, Ivkovic S, et al. Short-Term Fish Oil Treatment Changes the Composition of Phospholipids While Not Affecting the Expression of Mfsd2a Omega-3 Transporter in the Brain and Liver of the 5xFAD Mouse Model of Alzheimer’s Disease. Nutrients. 2018; 10(9).
33. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006; 26(40):10129–40. https://doi.org/10.1523/JNEUROSCI.1202-06.2006 PMID: 17021169
34. Eimer WA, Vassar R. Neuron loss in the 5xFAD mouse model of Alzheimer’s disease correlates with intraneuronal Abeta42 accumulation and Caspase-3 activation. Mol Neurodegeneration. 2013; 8:2. https://doi.org/10.1186/1750-1326-8-2 PMID: 23316765
35. Buskila Y, Crowe SE, Ellis-Davies GC. Synaptic deficits in layer 5 neurons precede overt structural decay in 5xFAD mice. Neuroscience. 2013; 254:152–9. https://doi.org/10.1016/j.neuroscience.2013.09.016 PMID: 24055664
36. Bolte S, Cordelier FP. A guided tour into subcellular colocalization analysis in light microscopy. J Microsc. 2006; 224(Pt 3):213–32. https://doi.org/10.1111/j.1365-2818.2006.01706.x PMID: 17210054

37. Manders EM, Stap J, Brakenhoff GJ, van Driel R, Aten JA. Dynamics of three-dimensional replication patterns during the S-phase, analysed by double labelling of DNA and confocal microscopy. J Cell Sci. 1992; 103:857–62.

38. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000; 6(8):916–9. https://doi.org/10.1038/78682 PMID: 10932230

39. Koenigs-knecht J, Landreth G. Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. J Neurosci. 2004; 24(44):9838–46. https://doi.org/10.1523/JNEUROSCI.2557-04.2004 PMID: 15525768

40. Hopperton KE, Trepanier MO, Giuliano V, Bazinet RP. Brain omega-3 polyunsaturated fatty acids modulate microglia cell number and morphology in response to intracerebroventricular amyloid-beta 1–40 in mice. J Neuroinflammation. 2016; 13(1):257. https://doi.org/10.1186/s12974-016-0721-5 PMID: 27688126

41. Michaelis ML, Seyb KI, Ansar S. Cytoskeletal integrity as a drug target. Curr Alzheimer Res. 2005; 2(2):227–9. PMID: 15974922

42. Montagne A, Zhao Z, Zlokovic BV. Alzheimer’s disease: A matter of blood-brain barrier dysfunction? J Exp Med. 2017; 214(11):3151–69. https://doi.org/10.1084/jem.20171406 PMID: 29061693

43. Iqbal K, Grundke-Iqbal I. Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med. 2008; 12(1):38–55. https://doi.org/10.1111/j.1582-4934.2008.00225.x PMID: 18194444

44. Saul A, Sprenger F, Bayer TA, Wirths O. Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer’s disease. Neurobiol Aging. 2013; 34(11):2564–73. https://doi.org/10.1016/j.neurobiolaging.2013.05.003 PMID: 23747045

45. Devassy JG, Leng S, Gabbs M, Monirujjaman M, Aukema HM. Omega-3 Polyunsaturated Fatty Acids and Oxylipins in Neuroinflammation and Management of Alzheimer Disease. Adv Nutr. 2016; 7(5):905–16. https://doi.org/10.3945/an.116.012187 PMID: 27633106

46. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci. 1991; 12(10):383–8. PMID: 1763432

47. Famenini S, Rigali EA, Olivera-Perez HM, Dang J, Chang MT, Halder R, et al. Increased intermediate M1-M2 macrophage polarization and improved cognition in mild cognitive impairment patients on omega-3 supplementation. FASEB J. 2017; 31(1):148–60. https://doi.org/10.1096/fj.201600677RR PMID: 27677546
56. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002; 23(11):549–55. PMID: 12404108

57. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25(12):677–86. https://doi.org/10.1016/j.it.2004.09.015 PMID: 15530839

58. Koenigsknecht-Talbott J, Landreth GE. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci. 2005; 25(36):8240–9. https://doi.org/10.1523/JNEUROSCI.1808-05.2005 PMID: 16148231

59. Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE, et al. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver X receptor s. Proc Natl Acad Sci U S A. 2007; 104(25):10601–6. https://doi.org/10.1073/pnas.0701096104 PMID: 17563384

60. Goerdt S, Orfano CE. Other functions, other genes: alternative activation of antigen-presenting cells. Immunity. 1999; 10(2):137–42. PMID: 10072066

61. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015; 14(4):388–405. https://doi.org/10.1016/S1474-4422(15)70016-5 PMID: 25792098

62. Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 2014; 40(2):274–88. https://doi.org/10.1016/j.immuni.2014.01.006 PMID: 24530056

63. Luo XG, Chen SD. The changing phenotype of microglia from homeostasis to disease. Transl Neurodegener. 2012; 1(1):9. https://doi.org/10.1186/2047-9158-1-9 PMID: 23210447

64. Stout RD. Editorial: macrophage functional phenotypes: no alternatives in dermal wound healing? J Leukoc Biol. 2010; 87(1):19–21. https://doi.org/10.1189/jlb.0509311 PMID: 20047887

65. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008; 451(7179):720–4. https://doi.org/10.1038/nature06616 PMID: 18256671

66. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med. 2001; 7(3):369–72. https://doi.org/10.1038/85525 PMID: 11231639

67. Wogulis M, Wright S, Cunningham D, Chilcote T, Powell K, Rydel RE. Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J Neurosci. 2005; 25(5):1071–80. https://doi.org/10.1523/JNEUROSCI.2381-04.2005 PMID: 15689542

68. O’Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, Herron CE, et al. Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci. 2010; 30(43):14411–9. https://doi.org/10.1523/ JNEUROSCI.3537-10.2010 PMID: 20980598

69. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol. 2010; 6(2):108–19. https://doi.org/10.1038/nrneurol.2009.219 PMID: 20140000

70. Grathwohl SA, Kalin RE, Bolmont T, Prokop S, Winkelman G, Kaeser SA, et al. Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat Neurosci. 2009; 12(11):1361–3. https://doi.org/10.1038/nn.2432 PMID: 19838177

71. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012; 367(9):795–804. https://doi.org/10.1056/NEJMoa1202753 PMID: 22784036

72. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013; 79(6):1094–108. https://doi.org/10.1016/j.neuron.2013.07.037 PMID: 24050400